Bacteroides eggerthii
Selected indexed studies
- Bacteroides eggerthii: a new human gut probiotic against metabolic dysfunction-associated steatotic liver disease. (Clin Mol Hepatol, 2025) [PMID:41360084]
- Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector. (Clin Mol Hepatol, 2026) [PMID:41146521]
- Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective. (Toxins (Basel), 2022) [PMID:35324673]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bacteroides eggerthii: a new human gut probiotic against metabolic dysfunction-associated steatotic liver disease. (2025) pubmed
- Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector. (2026) pubmed
- Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective. (2022) pubmed
- Screening of Fecal Bacteroides Strains and Discovery of Bacteroides eggerthii S13-F8 with Protective Effects Against Chemotherapy-Induced Diarrhea. (2026) pubmed
- The human gut Bacteroides eggerthii expresses a new galactofuranose-containing lipooligosaccharide with weak immunostimulatory properties. (2025) pubmed
- Hepatoprotective Potential of Bacteroides eggerthii on Fatty Liver Disease: A Mouse Model Study. (2025) pubmed
- (1)H, (13)C, (15)N resonance assignment of the enzyme KdgF from Bacteroides eggerthii. (2022) pubmed
- Action and cooperation in alginate degradation by three enzymes from the human gut bacterium Bacteroides eggerthii DSM 20697. (2024) pubmed
- Cloning, expression, and characterization of a novel heparinase I from Bacteroides eggerthii. (2020) pubmed
- Characterization of a novel multidomain CE15-GH8 enzyme encoded by a polysaccharide utilization locus in the human gut bacterium Bacteroides eggerthii. (2021) pubmed